Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMichael H. TomassonMBMelissa L. Bates

Discussion

Loading...

Member takes

Overview

Single-cell RNA sequencing demonstrates venetoclax-based therapy alters gene expression in bone marrow of AML patients, suggesting impacts on hematopoietic stem cells.

Key Points

  • The research aims to investigate the transcriptional changes in bone marrow during venetoclax-based therapy for acute myeloid leukemia.
  • Analyzed 10 bone marrow samples from AML patients treated with venetoclax and hypomethylating agents.
  • Utilized single-cell RNA sequencing to assess cellular diversity and gene expression dynamics.
  • Employing Seurat for clustering and UMAP reduction to map cellular populations.
  • Identified various hematopoietic populations including stem cells and immature progenitors during therapy.
  • Observations of gene expression showed downregulation of pro-survival genes like FKBP5 and BCL-2 in stem cells.
  • Differential expression indicated transcriptional remodeling associated with treatment response.

Cite This Study

Tomasson et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce8https://doi.org/10.1182/blood-2025-1499
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS2025
  2. 2Abstract 5852: Tumor gene expression patterns affecting response to BCl-2 inhibitor venetoclax in acute myeloid leukemia2024
  3. 3Abstract 3400: Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms2024
  4. 4Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025
  5. 5Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia2025 · 1 citations